Nov 17 (Reuters) -

Hims & Hers Health ( HIMS ) has appointed Deb Autor as its

first chief policy officer to lead public policy and government

functions, the telehealth firm said on Monday.

Autor brings more than three decades of experience, having

served as the deputy commissioner for global regulatory

operations and policy at the U.S. Food and Drug Administration

as well as having held a senior role in AstraZeneca ( AZN ).

She has been a member of the Hims & Hers' board since last

year, and will continue in that role.

Autor's appointment comes as Hims & Hers scales its

engagement with regulators and policymakers, it said.

In September, Hims came under the FDA's scrutiny for what

the agency called misleading marketing.

Hims has also shifted to selling "personalized" versions

of semaglutide, the active ingredient in Novo Nordisk's

weight-loss drug Wegovy, following the government's ban on the

mass production of copies.

In the new role, Autor will collaborate with consumers,

telehealth platforms, providers, pharmaceutical companies,

policymakers, and regulators, Hims said.